The present invention relates to a composition for preventing hair loss or promoting hair growth, comprising ginsenoside Rg4 or a mixture of ginsenosides Rg2, Rg4, Rg6, and Rh1 as an active ingredient. Treatment with ginsenoside Rg4 or the mixture of ginsenosides Rg2, Rg4, Rg6, and Rh1 in human hair follicle dermal papilla cells exhibits a desirable effect of forming three-dimensional spheres capable of inducing hair follicle formation and growth and increasing the size thereof, exhibits a desirable effect of activating Wnt/β-catenin signaling, which is important for hair follicle cell activation and regeneration, and exhibits a desirable effect of increasing the expression levels of ALPL, VCAN, BMP2, and FGF7 genes, which are important for hair follicle formation and growth. Thus, ginsenoside Rg4 or the mixture of ginsenosides Rg2, Rg4, Rg6, and Rh1 can be usefully utilized as a composition for preventing hair loss and promoting hair growth.

Disclosed herein are methods and compositions for reducing and/or preventing hair greying in a subject.

A pharmaceutical composition or a cosmetic composition for treating hair loss, or promoting hair growth is described. The composition according to the present invention exhibits an excellent effect of treating hair loss and promoting hair growth, and can be safely used regardless of sex and age.

The purpose of the present invention is to provide an oil-in-oil emulsified cosmetic having exceptional transfer resistance after application, luster, excellent spread during application, and especially exceptional cosmetic durability. The present invention pertains to an oil-in-oil emulsified cosmetic characterized by containing (a) 5-80 mass % of a nonvolatile hydrocarbon oil and/or nonvolatile ester oil, (b) 1-70 mass % of a nonvolatile silicone oil, and (c) 2-12 mass % of a spherical powder having an average particle size of 1-10 μm, the oil-in-oil emulsified cosmetic moreover being characterized in that the (a) nonvolatile hydrocarbon oil and/or nonvolatile ester oil and the (b) nonvolatile silicone oil separate when mixed at 25° C. The blend ratio (mass ratio) of the (a) nonvolatile hydrocarbon oil and/or nonvolatile ester oil and the (b) nonvolatile silicone oil is preferably (a)/[(a)+(b)]=0.4-0.8.

The present invention relates to a retinal-containing multilamellar vesicle and, more specifically, to a retinal-containing multilamellar vesicle comprising 0.01-5% by weight of retinal, 0.1-10% by weight of rapeseed sterol, 0.1-10% by weight of phytosteryl/behenyl/octyldodecyl lauroyl glutamate, 0.1-8% by weight of polyglyceryl-10 oleate, 0.1-10% by weight of cholesterol, 0.01-5% by weight of hydrogenated lecithin, 0.01-5% by weight of ceramide, 1-15% by weight of squalane, 0.1-10% by weight of vegetable butter, 3-30% by weight of oily liquid, 1-20% by weight of glycerin, and 30-70% by weight of water, and to a cosmetic composition comprising same.

The present invention relates to a retinal-containing multilamellar vesicle and, more specifically, to a retinal-containing multilamellar vesicle comprising 0.01-5% by weight of retinal, 0.1-10% by weight of rapeseed sterol, 0.1-10% by weight of phytosteryl/behenyl/octyldodecyl lauroyl glutamate, 0.1-8% by weight of polyglyceryl-10 oleate, 0.1-10% by weight of cholesterol, 0.01-5% by weight of hydrogenated lecithin, 0.01-5% by weight of ceramide, 1-15% by weight of squalane, 0.1-10% by weight of vegetable butter, 3-30% by weight of oily liquid, 1-20% by weight of glycerin, and 30-70% by weight of water, and to a cosmetic composition comprising same.

The present invention provides a process for preparation of compositions comprising novel mogrosides from fruit of Siraitia grosvenorii. The compositions have superior organoleptic properties compared to known mogroside compositions and are useful in wider range of consumables including foods and beverages.

The present invention provides a process for preparation of compositions comprising novel mogrosides from fruit of Siraitia grosvenorii. The compositions have superior organoleptic properties compared to known mogroside compositions and are useful in wider range of consumables including foods and beverages.

The present invention provides for bioavailable oral dosage forms containing esters of 17-hydroxyprogesterone as well as related methods. The oral dosage forms can be formulated for pregnancy support and can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. In another embodiment, a pharmaceutically acceptable oral dosage form for pregnancy support is provided. The pharmaceutically acceptable oral dosage can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. The oral dosage form can, when measured using a USP Type-II dissolution apparatus in 900 mL of deionized water with 0.5 (w/v) of sodium lauryl sulfate at 50 RPM at 37° C., release at least 20 wt % of the dose of the ester of 17-hydroxyprogesterone after 60 minutes, or in the alternative release at least 20 wt % more after 60 minutes than an equivalently dosed oral dosage form without the carrier.

The present invention provides for bioavailable oral dosage forms containing esters of 17-hydroxyprogesterone as well as related methods. The oral dosage forms can be formulated for pregnancy support and can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. In another embodiment, a pharmaceutically acceptable oral dosage form for pregnancy support is provided. The pharmaceutically acceptable oral dosage can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. The oral dosage form can, when measured using a USP Type-II dissolution apparatus in 900 mL of deionized water with 0.5 (w/v) of sodium lauryl sulfate at 50 RPM at 37° C., release at least 20 wt % of the dose of the ester of 17-hydroxyprogesterone after 60 minutes, or in the alternative release at least 20 wt % more after 60 minutes than an equivalently dosed oral dosage form without the carrier.